What is the drug of choice for Acinetobacter urinary tract infection?

Drug of Choice for Acinetobacter baumannii Urinary Tract Infection

For Acinetobacter baumannii UTI, colistin (polymyxin E) is the drug of choice, administered as colistimethate sodium with a loading dose of 5 mg CBA/kg IV followed by maintenance dosing based on creatinine clearance, for 5-7 days. 1

Treatment Algorithm Based on Resistance Pattern

For Carbapenem-Susceptible Acinetobacter baumannii

• Carbapenems remain first-line in areas with low carbapenem resistance rates 2
• Imipenem 0.5-1 g IV q6h or Meropenem 2 g IV q8h 2
• However, this scenario is increasingly rare given global resistance patterns

For Carbapenem-Resistant Acinetobacter baumannii (CRAB) - Most Common Scenario

Primary Options:

1. Colistin (Polymyxin E) - Most consistently effective 2, 3

   • Loading dose: 5-9 million IU IV 2
   • Maintenance: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h 1
   • Duration: 5-7 days for UTI 1
   • Critical caveat: Colistin demonstrates nephrotoxicity in 33% of cases 2, but remains most active in vitro 4

2. Sulbactam (as Ampicillin-Sulbactam) - Preferred when MIC ≤4 mg/L 2

   • Dose: 9-12 g/day sulbactam in 3-4 divided doses 2
   • Administer as 4-hour infusion for optimal PK/PD 2
   • Advantage: Superior safety profile compared to colistin with comparable efficacy 2
   • Evidence: In comparative studies, sulbactam showed similar clinical cure rates to colistin but with significantly lower nephrotoxicity (15.3% vs 33%) and lower 30-day mortality 2

Key Clinical Decision Points

When to Choose Sulbactam Over Colistin:

• If susceptibility testing shows sulbactam MIC ≤4 mg/L 2
• Patient has pre-existing renal impairment
• Goal is to preserve colistin for more severe infections 2

When Colistin is Mandatory:

• Sulbactam MIC >4 mg/L
• Documented colistin susceptibility with resistance to other agents
• Empirical therapy in high-risk settings pending susceptibilities 2

Combination Therapy Considerations

For UTI specifically, monotherapy is generally adequate 1. However, combination therapy may be considered for:

• Severe sepsis/septic shock from urinary source
• Documented high colistin MIC (≥1 μg/mL) - consider colistin + doripenem 5

Important: Recent high-quality RCTs (AIDA and OVERCOME trials) showed no mortality benefit for colistin-carbapenem combinations in CRAB infections overall 6, though these primarily studied pneumonia and bacteremia, not isolated UTI.

Critical Pitfalls to Avoid

1. Do not use carbapenems empirically in areas with high CRAB prevalence (>20% resistance) 2
2. Do not use tigecycline for UTI - inadequate urinary concentrations despite systemic activity 2
3. Do not rely on automated susceptibility testing for sulbactam - use E-test with MIC ≤4 mg/L as susceptibility breakpoint 2
4. Do not underdose colistin - loading dose is essential as steady-state takes 2-3 days without it 2
5. Avoid piperacillin-tazobactam and fluoroquinolones - resistance rates exceed 50% in most settings 4

Duration of Therapy

• Uncomplicated UTI: 5-7 days 1
• Complicated UTI: 5-10 days 1
• Adjust based on clinical response and source control

Emerging Options

Sulbactam-durlobactam was FDA-approved in 2023 for CRAB infections 7 and represents a promising future option, though current guidelines and most clinical experience focus on the agents discussed above.